Table 3.

Diagnostic accuracy of IL-13, miRNA-135a, and vit D to predict treatment failure and HCC with the best predictive cut offs.

	AUC (95%CI)	SE	SP	+LR
(a) For prediction of DAA treatment failure
IL-13 (>135.9 pg/mL)	0.999 (0.998–1)	100	96.1	25.9
miRNA135a (>3.562-fold change)	0.978 (0.968–0.989)	97.14	91.59	11.7
Vit D (<21.13 ng/mL)	0.851 (0.807–0.895)	82.9	82.7	4.8
(b) For prediction of HCC development
IL-13 (>249 pg/mL)	0.992 (0.987–0.997)	100	98.4	61.7
miRNA135a (>3.66 fold change)	0.976 (0.964–0.989)	100	88.96	9.06
Vit D (<21.04 ng/mL)	0.872 (0.809–0.935)	92	79.9	4.6
(c) For prediction of DAA treatment failure in non-cirrhotic patients
IL-13 (>135.9 pg/mL)	0.998 (0.995–1.000)	100	96.9	32.5
mRNA135a (>3.562-fold change)	0.967 (0.950–0.983)	96.2	91.7	11.6
Vit D (<24.11 ng/mL)	0.861 (0.780–0.942)	84.6	83.7	5.2
(d) For prediction of DAA treatment failure in cirrhotic patients
Il-13 (>166.3 pg/mL)	1 (0.979–1.000)	100	100	-
mRNA135a (>3.643 fold change)	0.985 (0.971–1.000)	97.73	92.42	12.9
Vit D (<22.5 ng/mL)	0.657 (0.573–0.742)	86.4	50	1.7
(e) For prediction of HCC development in cirrhotic patients
Il-13 (>232.5 pg/mL)	0.949 (0.9184–0.9798)	100	90.1	10.1
mRNA135a (>3.643 fold change)	0.936 (0.900–0.972)	100	81.46	5.4
Vit D (<22.5 ng/mL)	0.6575 (0.558–0.757)	92	46.4	1.7

AUC: area under the curve; CI: confidence interval; +LR: positive likelihood ratio, SE: sensitivity; SP: specificity.